<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923804</url>
  </required_header>
  <id_info>
    <org_study_id>1051-001-PRO-19012015</org_study_id>
    <nct_id>NCT02923804</nct_id>
  </id_info>
  <brief_title>Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients When Added to Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pronova BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nutrasource Pharmaceutical and Nutraceutical Services, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pronova BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, placebo-controlled, double-blind trial to determine&#xD;
      the effect of high concentrate omega-3 capsules on the omega-3 status of patients with&#xD;
      non-alcoholic fatty liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with non-alcoholic fatty liver (simple steatosis) confirmed within the last year by&#xD;
      ultrasound or other imaging modality will be recruited to the study. Subjects will be&#xD;
      randomized to a treatment arm of high concentrate capsules or placebo for a 6 month treatment&#xD;
      period.Omega-3 content of red blood cells (omega-3 index) will be measured for primary&#xD;
      endpoint assessment. Quantitative MRI will be performed to determine the effect on liver fat&#xD;
      content.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 1, 2017</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• The primary endpoint is the difference in mean percent changes from baseline (Week 24 each with baseline subtracted) between placebo and omega-3 groups</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Difference in mean percent change from baseline to end-of-treatment in RBC EPA and RBC DHA (percentage of lipids and quantitative measurements)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Difference in mean percent change from baseline to end of treatment in omega-6: omega-3 ratios.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of omega-3 on changes in liver fat as determined by MRI-PDFF</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Non Alcoholic Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules of 1g concentrated omega-3 taken daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olive oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 capsules of 1g olive oil taken daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <description>3x 1g capsules taken daily for 6 months</description>
    <arm_group_label>Omega-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Olive oil</intervention_name>
    <description>3x 1g capsules taken daily for 6 months</description>
    <arm_group_label>Olive oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented history of clinical diagnosis of NAFLD by ultrasound, MRI or biopsy within&#xD;
             one (1) year prior to screening (V1). If the diagnostic test date is greater than one&#xD;
             (1) year, abdominal ultrasound will be repeated at (V1) and must confirm a diagnosis&#xD;
             of NAFLD.&#xD;
&#xD;
          2. Men or women, ≥18 years of age.&#xD;
&#xD;
          3. BMI between 18.0 and 39.9 kg/m2.&#xD;
&#xD;
          4. Non-smokers (&gt;3 months of non-smoking).&#xD;
&#xD;
          5. If on a statin regimen, history (&gt; 1 month stable dose) of taking a statin medication&#xD;
             (HMG-CoA reductase inhibitor example: Lipitor, Zocor, Crestor, Pravachol, Lescol,&#xD;
             Livalo, etc).&#xD;
&#xD;
          6. Able to understand and cooperate with study procedures, and have signed a written&#xD;
             informed consent prior to any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of NASH.&#xD;
&#xD;
          2. Bilirubin &gt;2x ULN.&#xD;
&#xD;
          3. Other causes of liver inflammation including Hepatitis A, B or C, HIV, confirmed or&#xD;
             suspected cirrhosis, Wilson's disease, autoimmune hepatitis, hemochromatosis,&#xD;
             alcoholic steatohepatitis, pancreatitis, or prescription medications known to cause&#xD;
             liver damage, or known to be hepatotoxic.&#xD;
&#xD;
          4. Subjects with a history of bariatric surgery.&#xD;
&#xD;
          5. Significant weight loss (&gt; 5% body weight) or rapid weight loss (&gt;1.6 kg/week), within&#xD;
             six months of screening.&#xD;
&#xD;
          6. Current or recent (within six months of screening) history of significant&#xD;
             gastrointestinal, renal, pulmonary, hepatic or biliary disease, endocrine diseases or&#xD;
             other invasive weight loss treatments (Type II Diabetes permitted, and stable (&gt; 3&#xD;
             months) thyroid disorders).&#xD;
&#xD;
          7. Individual taking prescription or over-the-counter medications (including dietary&#xD;
             supplements, see Appendix 1) known to alter lipid metabolism, within four (4) weeks of&#xD;
             randomization. These medications include (but are not limited to) the following: bile&#xD;
             acid sequestrants, cholesterol absorption inhibitors, niacin or fibrates,&#xD;
&#xD;
          8. Individuals taking prescription omega-3 fatty acids.&#xD;
&#xD;
          9. Use of supplements including Omega-3s and Omega-6s, other oil-based supplements,&#xD;
             phytosterols, Vitamin E, prebiotics and probiotics, or any weight loss supplements&#xD;
             within four (4) weeks of randomization (multivitamins and minerals containing Vitamin&#xD;
             E are permitted).&#xD;
&#xD;
         10. Use of systemic corticosteroids, androgens (except androgens for hypogonadism to&#xD;
             restore normal levels), phenytoin, erythromycin and other macrolides,&#xD;
             thiazolidinediones (e.g. pioglitazone), and thyroid hormones (except stable-dose&#xD;
             thyroid replacement therapy for four (4) weeks prior to enrollment).&#xD;
&#xD;
         11. Use of the anticoagulants warfarin (Coumadin), dabigatran (Pradaxa), apixaban&#xD;
             (Eliquis) or rivaroxaban (Xarelto). NOTE: Anti-platelet agents such as Plavix are&#xD;
             allowed.&#xD;
&#xD;
         12. Pregnant or lactating women or women of childbearing potential, who are not using an&#xD;
             approved method of contraception. A woman is considered to be of childbearing&#xD;
             potential unless she is post-hysterectomy, one or more years postmenopausal, or one or&#xD;
             more years post-tubal ligation.&#xD;
&#xD;
         13. History of significant cardiovascular or coronary heart disease (CVD or CHD) as&#xD;
             defined by having had a coronary artery bypass procedure, coronary stent or&#xD;
             angioplasty, or myocardial infarction in the previous six (6) months.&#xD;
&#xD;
         14. History of cancer, other than non-melanoma skin cancer and basal cell carcinoma,&#xD;
             within the previous five years.&#xD;
&#xD;
         15. Poorly controlled or uncontrolled hypertension (systolic blood pressure ≥160 mmHg&#xD;
             and/or diastolic blood pressure ≥95 mmHg).&#xD;
&#xD;
         16. Recent history of prolonged alcohol (&gt;3 months) use (within past 6 months) or&#xD;
             excessive alcohol use, defined as &gt;14 drinks per week (one drink = 12 oz. beer, 4 oz.&#xD;
             wine, 1.5 oz. hard liquor).&#xD;
&#xD;
         17. Exposure to any investigational agent within four (4) weeks prior to Visit 1.&#xD;
&#xD;
         18. Subjects planning to undergo surgery during the study period or up to 1 month after&#xD;
             the study&#xD;
&#xD;
         19. Any serious psychiatric disease or disorder, which, in the opinion of the&#xD;
             investigator, would preclude the subject from participating in the study.&#xD;
&#xD;
         20. Any known intolerance to the investigational ingredients of this medical food.&#xD;
&#xD;
         21. Has a condition the Investigator believes would interfere with the evaluation of the&#xD;
             subject, or may put the subject at undue risk during the course of the study,&#xD;
             including potentially abnormal lab results, due to a traumatic event.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Tobin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BASF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hialeah</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Worth</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lauderdale Lakes</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>steatosis</keyword>
  <keyword>NAFL</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Polyunsaturated fatty acids</keyword>
  <keyword>omega-3</keyword>
  <keyword>EPA</keyword>
  <keyword>DHA</keyword>
  <keyword>fish oil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

